PL369607A1 - Środki naśladujące dysmutazę ponadtlenkową do leczenia zaburzeń i chorób oczu - Google Patents

Środki naśladujące dysmutazę ponadtlenkową do leczenia zaburzeń i chorób oczu

Info

Publication number: PL369607A1
Authority: PL; Poland
Prior art keywords: treatment; diseases; superoxide dismutase; ocular disorders; dismutase mimics
Prior art date: 2001-12-14

Application number

PL02369607A

Other languages

English (en)

Other versions

PL210225B1 (pl

Inventor

Peter G. Klimko

Robert J.Jr. Collier

Mark R. Hellberg

Original Assignee

Alcon, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-14

Filing date

2002-12-06

Publication date

2005-05-02

2002-12-06 Application filed by Alcon, Inc. filed Critical Alcon, Inc.

2005-05-02 Publication of PL369607A1 publication Critical patent/PL369607A1/pl

2011-12-30 Publication of PL210225B1 publication Critical patent/PL210225B1/pl

Links

208000022873 Ocular disease Diseases 0.000 title 2
102000019197 Superoxide Dismutase Human genes 0.000 title 1
108010012715 Superoxide dismutase Proteins 0.000 title 1
WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 abstract 1
201000010183 Papilledema Diseases 0.000 abstract 1
206010038886 Retinal oedema Diseases 0.000 abstract 1
206010064930 age-related macular degeneration Diseases 0.000 abstract 1
201000011195 retinal edema Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL369607A 2001-12-14 2002-12-06 Zastosowanie związku naśladującego dysmutazę ponadtlenkową jako środka do leczenia zaburzeń i chorób oczu PL210225B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US34038901P	2001-12-14	2001-12-14

Publications (2)

Publication Number	Publication Date
PL369607A1 true PL369607A1 (pl)	2005-05-02
PL210225B1 PL210225B1 (pl)	2011-12-30

Family

ID=23333158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL369607A PL210225B1 (pl)	2001-12-14	2002-12-06	Zastosowanie związku naśladującego dysmutazę ponadtlenkową jako środka do leczenia zaburzeń i chorób oczu

Country Status (18)

Country	Link
US (2)	US7759333B2 (pl)
EP (1)	EP1463563B1 (pl)
JP (1)	JP2005513063A (pl)
KR (1)	KR100951606B1 (pl)
CN (2)	CN1620325A (pl)
AT (1)	ATE422944T1 (pl)
BR (1)	BR0214957A (pl)
CA (1)	CA2470721C (pl)
CY (1)	CY1108983T1 (pl)
DE (1)	DE60231246D1 (pl)
DK (1)	DK1463563T3 (pl)
ES (1)	ES2319399T3 (pl)
MX (1)	MXPA04005601A (pl)
PL (1)	PL210225B1 (pl)
PT (1)	PT1463563E (pl)
SI (1)	SI1463563T1 (pl)
WO (1)	WO2003051458A1 (pl)
ZA (1)	ZA200404435B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1620325A (zh) *	2001-12-14	2005-05-25	艾尔科公司	治疗眼睛障碍和疾病的超氧化物歧化酶模拟物
AU2004305531B2 (en) *	2003-12-11	2009-11-26	Alcon, Inc.	Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
US7803931B2 (en)	2004-02-12	2010-09-28	Archemix Corp.	Aptamer therapeutics useful in the treatment of complement-related disorders
US8598150B1 (en)	2008-04-02	2013-12-03	Jonathan R. Brestoff	Composition and method for affecting obesity and related conditions
US8987245B2 (en)	2008-04-02	2015-03-24	Jonathan R. Brestoff Parker	Composition and method for affecting obesity and related conditions
NZ593536A (en)	2008-12-19	2013-07-26	Genentech Inc	Quinoline derivatives and methods of use
PT2433640T (pt)	2010-09-24	2020-04-03	Omnivision Gmbh	Composição compreendendo sod, luteína e zeaxantina
KR101214364B1 (ko) *	2011-02-15	2012-12-21	한림대학교 산학협력단	수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
CA2849456C (en) *	2011-09-26	2021-12-07	Galera Therapeutics, Llc	Methods for treatment of diseases
KR102531246B1 (ko) *	2021-12-23	2023-05-11	주식회사 제노포커스	수퍼옥시드 디스뮤타제 및 이의 건성 황반변성의 예방 또는 치료용 용도
CN119855604A (zh) *	2022-05-16	2025-04-18	杰诺福克斯有限公司	超氧化物歧化酶及其在预防或治疗糖尿病视网膜病变或葡萄膜炎中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5209926A (en) *	1990-06-12	1993-05-11	Insite Vision Incorporated	Aminosteroids for ophthalmic use
US5124154A (en) *	1990-06-12	1992-06-23	Insite Vision Incorporated	Aminosteroids for ophthalmic use
US5994339A (en)	1993-10-15	1999-11-30	University Of Alabama At Birmingham Research Foundation	Oxidant scavengers
US6127356A (en)	1993-10-15	2000-10-03	Duke University	Oxidant scavengers
SE9402816D0 (sv)	1994-08-24	1994-08-24	Pharmacia Ab	Method and meams for drug administration
US6214817B1 (en) *	1997-06-20	2001-04-10	Monsanto Company	Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en)	1997-06-20	2001-01-30	G.D. Searle & Co.	Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
JP2001521939A (ja) *	1997-11-03	2001-11-13	デューク・ユニバーシティー	置換されたポルフィリン類
AU5251999A (en)	1998-08-04	2000-02-28	Wisconsin Alumni Research Foundation	Method of reducing retinal ganglion cell degeneration
GB9817845D0 (en)	1998-08-17	1998-10-14	Glaxo Group Ltd	Chemical compounds
WO2000023568A2 (en)	1998-10-06	2000-04-27	Albert Einstein College Of Medicine Of Yeshiva University	Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
US7445641B1 (en)	1999-05-27	2008-11-04	Pharmacia Corporation	Biomaterials modified with superoxide dismutase mimics
CN1620325A (zh) *	2001-12-14	2005-05-25	艾尔科公司	治疗眼睛障碍和疾病的超氧化物歧化酶模拟物

2002
- 2002-12-06 CN CNA028280806A patent/CN1620325A/zh active Pending
- 2002-12-06 DK DK02786915T patent/DK1463563T3/da active
- 2002-12-06 KR KR1020047008842A patent/KR100951606B1/ko not_active Expired - Fee Related
- 2002-12-06 PL PL369607A patent/PL210225B1/pl unknown
- 2002-12-06 MX MXPA04005601A patent/MXPA04005601A/es active IP Right Grant
- 2002-12-06 CN CNA2006100774968A patent/CN101092432A/zh active Pending
- 2002-12-06 BR BR0214957-5A patent/BR0214957A/pt not_active Application Discontinuation
- 2002-12-06 US US10/498,721 patent/US7759333B2/en not_active Expired - Fee Related
- 2002-12-06 DE DE60231246T patent/DE60231246D1/de not_active Expired - Lifetime
- 2002-12-06 AT AT02786915T patent/ATE422944T1/de active
- 2002-12-06 EP EP02786915A patent/EP1463563B1/en not_active Expired - Lifetime
- 2002-12-06 SI SI200230808T patent/SI1463563T1/sl unknown
- 2002-12-06 JP JP2003552386A patent/JP2005513063A/ja active Pending
- 2002-12-06 CA CA2470721A patent/CA2470721C/en not_active Expired - Fee Related
- 2002-12-06 ES ES02786915T patent/ES2319399T3/es not_active Expired - Lifetime
- 2002-12-06 PT PT02786915T patent/PT1463563E/pt unknown
- 2002-12-06 WO PCT/US2002/039037 patent/WO2003051458A1/en not_active Ceased
2004
- 2004-06-04 ZA ZA200404435A patent/ZA200404435B/en unknown
2009
- 2009-04-14 CY CY20091100442T patent/CY1108983T1/el unknown
2010
- 2010-04-23 US US12/766,332 patent/US8003635B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2005513063A (ja)	2005-05-12
MXPA04005601A (es)	2004-12-06
BR0214957A (pt)	2004-12-14
ES2319399T3 (es)	2009-05-07
CA2470721C (en)	2011-07-12
PL210225B1 (pl)	2011-12-30
WO2003051458A1 (en)	2003-06-26
HK1069785A1 (en)	2005-06-03
US8003635B2 (en)	2011-08-23
ATE422944T1 (de)	2009-03-15
US7759333B2 (en)	2010-07-20
EP1463563B1 (en)	2009-02-18
CN1620325A (zh)	2005-05-25
US20100204194A1 (en)	2010-08-12
US20050032768A1 (en)	2005-02-10
KR20040063943A (ko)	2004-07-14
CN101092432A (zh)	2007-12-26
CA2470721A1 (en)	2003-06-26
SI1463563T1 (sl)	2009-06-30
AU2002351267B2 (en)	2007-04-05
AU2002351267A1 (en)	2003-06-30
CY1108983T1 (el)	2014-07-02
KR100951606B1 (ko)	2010-04-09
DK1463563T3 (da)	2009-04-20
DE60231246D1 (de)	2009-04-02
ZA200404435B (en)	2006-05-31
EP1463563A1 (en)	2004-10-06
PT1463563E (pt)	2009-03-19

Publication	Publication Date	Title
WO2004052227A3 (en)	2005-03-31	Superoxide dismutase mimics for the treatment of ocular disorders and diseases
CY1108983T1 (el)	2014-07-02	Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων
WO2002085248A3 (en)	2004-03-04	Prostanoids augment ocular drug penetration
WO2006069078A3 (en)	2007-08-09	Treatment of anal incontinence
MXPA04011612A (es)	2005-03-07	Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
AU780906C (en)	2006-04-27	Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body
AP1750A (en)	2007-06-23	Methods for treating ocular neovascular diseases
PL396553A1 (pl)	2012-01-30	Zastosowanie czynnika do wytwarzania leku do leczenia jaskry
MXPA03010655A (es)	2007-06-22	Gel oft??lmico de pirenzepina.
ATE539701T1 (de)	2012-01-15	Zusammengesetzte schlinge zur behandlung von inkontinenz
AU2002234806A1 (en)	2002-07-08	Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
WO1998039293A3 (en)	1998-11-05	13-thia prostaglandins for use in glaucoma therapy
WO2001068053A3 (en)	2002-08-29	Methods and compositions for treating and preventing posterior segment ophthalmic disorders
MXPA03009273A (es)	2004-02-12	AGENTE PARA EL TRATAMIENTO OFTaLMICO TOPICO DE LAS ENFERMEDADES INFLAMATORIAS OCULARES.
MXPA04000124A (es)	2004-05-21	Composicion farmaceutica para la terapia de cistitis intersticial.
WO2002067971A3 (en)	2003-12-31	Use of endostatin in the treatment of ocular neovascularization
BR0017163A (pt)	2003-01-14	Derivados 5-hidróxi-indazol para tratamento do glaucoma
WO2005013911A3 (en)	2005-05-12	Protective and therapeutic uses for tocotrienols
EP1567166A4 (en)	2009-06-17	SUPEROXIDE DISMUTASE MIMIC FOR THE TREATMENT OF EYE DISORDER AND DISEASES
AU2001259085A1 (en)	2001-10-30	Treatment of ocular neovascularization and related diseases
EP1297849A4 (en)	2006-10-18	CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES
PT1178819E (pt)	2004-04-30	Glutationa-redutase para a terapia e profilaxia da sida
WO2005058911A3 (en)	2005-08-25	Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
BRPI0417549A (pt)	2007-03-27	miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal
MXPA04001255A (es)	2004-05-27	Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.